54
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ebola virus causes sporadic outbreaks of lethal hemorrhagic fever in humans, but there is no currently approved therapy. Cells take up Ebola virus by macropinocytosis, followed by trafficking through endosomal vesicles. However, few factors controlling endosomal virus movement are known. Here we find that Ebola virus entry into host cells requires the endosomal calcium channels called two-pore channels (TPCs). Disrupting TPC function by gene knockout, small interfering RNAs, or small-molecule inhibitors halted virus trafficking and prevented infection. Tetrandrine, the most potent small molecule that we tested, inhibited infection of human macrophages, the primary target of Ebola virus in vivo, and also showed therapeutic efficacy in mice. Therefore, TPC proteins play a key role in Ebola virus infection and may be effective targets for antiviral therapy.

          Related collections

          Author and article information

          Journal
          Science
          Science (New York, N.Y.)
          1095-9203
          0036-8075
          Feb 27 2015
          : 347
          : 6225
          Affiliations
          [1 ] Texas Biomedical Research Institute, San Antonio, TX, USA.
          [2 ] The University of Texas Medical Branch, Galveston, TX, USA.
          [3 ] Center for Integrated Protein Science Munich (CIPSM) at the Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany.
          [4 ] Southwest Research Institute, San Antonio, TX, USA.
          [5 ] Institute for Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany.
          [6 ] Texas Biomedical Research Institute, San Antonio, TX, USA. rdavey@txbiomed.org.
          Article
          347/6225/995 NIHMS668876
          10.1126/science.1258758
          25722412
          3bb4b720-ff87-4dd2-b550-6930a95a7100
          Copyright © 2015, American Association for the Advancement of Science.
          History

          Comments

          Comment on this article